Next Article in Journal
Influence of Levamisole and Other Angiogenesis Inhibitors on Angiogenesis and Endothelial Cell Morphology in Vitro
Next Article in Special Issue
Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia
Previous Article in Journal
Effects of Ellagic Acid on Angiogenic Factors in Prostate Cancer Cells
Previous Article in Special Issue
Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
Cancers 2013, 5(3), 739-761; doi:10.3390/cancers5030739
Review

Synthetic Genetic Targeting of Genome Instability in Cancer

,
 and *
Received: 23 April 2013; in revised form: 3 June 2013 / Accepted: 6 June 2013 / Published: 24 June 2013
(This article belongs to the Special Issue Genomic Instability and Cancers)
View Full-Text   |   Download PDF [693 KB, uploaded 24 June 2013]   |   Browse Figures
Abstract: Cancer is a leading cause of death throughout the World. A limitation of many current chemotherapeutic approaches is that their cytotoxic effects are not restricted to cancer cells, and adverse side effects can occur within normal tissues. Consequently, novel strategies are urgently needed to better target cancer cells. As we approach the era of personalized medicine, targeting the specific molecular defect(s) within a given patient’s tumor will become a more effective treatment strategy than traditional approaches that often target a given cancer type or sub-type. Synthetic genetic interactions are now being examined for their therapeutic potential and are designed to target the specific genetic and epigenetic phenomena associated with tumor formation, and thus are predicted to be highly selective. In general, two complementary approaches have been employed, including synthetic lethality and synthetic dosage lethality, to target aberrant expression and/or function associated with tumor suppressor genes and oncogenes, respectively. Here we discuss the concepts of synthetic lethality and synthetic dosage lethality, and explain three general experimental approaches designed to identify novel genetic interactors. We present examples and discuss the merits and caveats of each approach. Finally, we provide insight into the subsequent pre-clinical work required to validate novel candidate drug targets.
Keywords: cancer; genome instability; tumor suppressor gene; oncogene; synthetic genetic approach; synthetic lethality; synthetic dosage lethality; cancer therapy cancer; genome instability; tumor suppressor gene; oncogene; synthetic genetic approach; synthetic lethality; synthetic dosage lethality; cancer therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Sajesh, B.V.; Guppy, B.J.; McManus, K.J. Synthetic Genetic Targeting of Genome Instability in Cancer. Cancers 2013, 5, 739-761.

AMA Style

Sajesh BV, Guppy BJ, McManus KJ. Synthetic Genetic Targeting of Genome Instability in Cancer. Cancers. 2013; 5(3):739-761.

Chicago/Turabian Style

Sajesh, Babu V.; Guppy, Brent J.; McManus, Kirk J. 2013. "Synthetic Genetic Targeting of Genome Instability in Cancer." Cancers 5, no. 3: 739-761.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert